Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (July 2024)
21 slides from Sona Nanotech's investor presentation, July 2024
Slide 1: A Novel 1-2 Punch Against Cancer
Sona’s THT Therapy: Cancer Tumor Volume Reduction & Immune System Activation A Novel 1-2 Punch Against Cancer July 2024 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Who we are
Who we are Sona’s Gold Nanorods (“GNRs”) o We make highly functional rod-shaped, gold nanoparticles ▪ Shape permits most efficient conversion of light to heat ▪ Aspect ratio enables them to be tuned to specific energy wavelengths to enable heating and potentially triggering of conjugated molecules ▪
Slide 4: What we do
What we do Targeted Hyperthermia Therapy (“THT”) Sona’s THT Cancer Therapy: • We inject gold nanorods into cancer tumors • We apply a near infrared light source • We heat the nanoparticles within a specific temperature range • This causes death of tumor cells This also causes neo-antigens to be pres
Slide 5: What we have done so far
What we have done so far Dalhousie Preclinical Efficacy Study A range of studies to establish the efficacy of the THT and resulting opportunities. Success from these proof-of-concept studies will support regulatory submissions for clinical trials The study was conducted with mice implanted with: Tri
Slide 6: Initial Treatment Results
What we have done so far Initial Treatment Results Results of initial treatment alone show: • one treatment reduced the primary tumor by an average of approximately 80% Tumor volume • cancer tumors can grow back after the first treatment Tumor volume (%Day 0) C 600 G 400 Control THT * = treated tumo
Slide 7: The Effects of Multiple THT Treatments
What we have done so far The Effects of Multiple THT Treatments Tumor Volume - B16 600 Tumor Volume - B16 Control Tumor Volume (mm3) Enhanced Tumor Reduction with Two THT Treatments THT single laser (B16 Melanoma Cancer 400 Mouse Tumor Model, n=3) THT double laser (n=3) 600 Control Tumor Volume (mm3
Slide 8: A Single THT Treatment Triggered A Systemic Immune Response
What we have done so far A Single THT Treatment Triggered A Systemic, Immune Response 4T1 – Breast Cancer B16 - Melanoma • Using a gentle controlled warming of the Ccl7 nanoparticles inside a tumor causes the new Ccl7 Cxcl10 Cxcl10 tumor antigens to be released, and enables Cxcl9 Cxcl9 the body's na
Slide 9: THT Enhanced The Immune System's Ability To Attack Cancer
What we have done so far THT Enhanced The Immune System’s Ability To Attack Cancer 4T1 Melanoma Model Study Data Dendritic cell count Macrophage count M1 count NK Cell count 2000 15000 5000 ✱ 20000 Cell count/10^6 cells Cell count/10^6 cells Cell count/10^6 cells Cell number/10^6 cells 4000 1500 100
Slide 10: THT Combined With IL-2
What we have done so far Tumor volume - B16 THT Combined With IL-2 600 • IL-2 is a standard immunotherapeutic drug used to treat cancer. Control Tumor Volume (mm3) IL-2 • IL-2 and other checkpoint inhibitors can 400 THT have a significant positive effect on THT+IL-2 cancer patients when they work. T
Slide 11: THT Showed A Vaccine-like Effect
What we have done so far THT Showed A Vaccine-like Effect Contralateral Tumor Volume - B16 400 In mice with one tumor treated Control with THT and IL-2, an abscopal Tumor volume (mm3) effect was seen whereby distant, 300 IL2 untreated tumors shrunk. THT (single treatment) Further, newly implanted 20
Slide 12: What we need to do from here
What we need to do from here FDA-vetted Development Milestones for THT Safety Studies Based on the substantial success the company has achieved in its preclinical studies, Sona's near-term objectives will focus on four areas: • Complete final analysis, publish in 2024 2025 medical journal and peer r
Slide 13: Improving Immunotherapy Response Rates By Only 10% Could Mean Longer Life For Millions
Improving Immunotherapy Response Rates By Only 10% Could Mean Longer Life For Millions Immunotherapy Response Rate in Study of 1678 Patients by Cancer Type 100% 90% 80% 70% 60% 50% 40% 30% Average response rate of 21% 20% 10% 0% Note: Patients treated with anti–programmed cell death 1 or programmed
Slide 14: Sona Has Engineered the Right Team to Develop Its THT Cancer Therapy
Sona Has Engineered the Right Team to Develop Its THT Cancer Therapy Board Mark Lievonen Walter Strapps PhD Neil Fraser Jim Megann Chairman Director Director Director o Led vaccine maker Sanofi- o CSO of Khosla Ventures o Led Medtronic Canada for ~20 o 25 years of experience in Pasteur to a billion-
Slide 15: Capitalization Table
Capitalization Table Market Capitalization Ownership Share Price C$0.30 Board and Market Cap. C$30M 16% Management 52 Week High/Low $0.56/$0.135 Capital Structure Issued & Outstanding 99M Options 6.0M Public 84% Warrants 3.1M As of July 2, 2024 sonanano.com 15
Slide 16: Recent News
Recent News aos ss ¥ Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results Sona Nanotech Announces Filing of Provisional Patent Application MARCH 25, 2024 MARCH 18, 2024 \ TEMaprreueverererten ses COMPANY NEWS, NEWS RELEASES: Sona’s Cancer Therapy Creates Sona Appoints Chief Medical
Slide 17: Thank you
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Thank you David Regan david@sonanano.com CEO Sona Nanotech Inc. +1 902 448 1416 CSE: SONA | OTCQB: SNANF sonanano.com 17
Slide 18: Appendix
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Appendix sonanano.com 18
Slide 19: Hyperthermia Triggers Antigen Presentation To The Immune System
Hyperthermia Triggers Antigen Presentation To The Immune System Gold nanorods Adapted from Pharmaceutics 13(8):1147 19
Slide 20: THT + Immunotherapeutic Drug Potentiates an Immune Response
THT + Immunotherapeutic Drug Potentiates an Immune Response THT shrinks tumors and increases survival in animal models. Sona’s new preclinical studies now establish that: 1. THT stimulates the innate immune system • Priming it to help fight the cancer 2. THT upregulates gene expression of inflammato
Slide 21: Summary Of Dalhousie University Study Findings
Summary Of Dalhousie University Study Findings • GNR-induced hyperthermia triggers STING/innate immune response, reducing tumor volume drastically. • Combination with intratumoral IL-2 therapy leads to: • durable tumor reduction • more CD8+ infiltration • increased CD8+ memory subsets, and • higher